EJEun-Seok Jeon

Eun-Seok Jeon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Eun-Seok Jeon has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Byung-Kwan Lim

    Department of Medicine, Cardiovascular Institute, Samsung Medical Center, Seoul, South Korea

    1 shared publication
  • Jae-Ok Shin

    From the Department of Medicine, Cardiovascular Institute, Samsung Medical Center (B.-K.L., J.-O.S., E.-S.J.); Medical Department, MSD Korea Ltd (S.-C.C.); ViroMed Limited, Technology Business Incubator (S.-H.H., J.-M.K., S.-S.Y); and Institute of Molecular Biology and Genetics (S.K.), Seoul National University, Seoul, South Korea.

    1 shared publication
  • Jong-Mook Kim

    From the Department of Medicine, Cardiovascular Institute, Samsung Medical Center (B.-K.L., J.-O.S., E.-S.J.); Medical Department, MSD Korea Ltd (S.-C.C.); ViroMed Limited, Technology Business Incubator (S.-H.H., J.-M.K., S.-S.Y); and Institute of Molecular Biology and Genetics (S.K.), Seoul National University, Seoul, South Korea.

    1 shared publication
  • Seong-Choon Choe

    From the Department of Medicine, Cardiovascular Institute, Samsung Medical Center (B.-K.L., J.-O.S., E.-S.J.); Medical Department, MSD Korea Ltd (S.-C.C.); ViroMed Limited, Technology Business Incubator (S.-H.H., J.-M.K., S.-S.Y); and Institute of Molecular Biology and Genetics (S.K.), Seoul National University, Seoul, South Korea.

    1 shared publication
  • Seong-Hyun Ho

    From the Department of Medicine, Cardiovascular Institute, Samsung Medical Center (B.-K.L., J.-O.S., E.-S.J.); Medical Department, MSD Korea Ltd (S.-C.C.); ViroMed Limited, Technology Business Incubator (S.-H.H., J.-M.K., S.-S.Y); and Institute of Molecular Biology and Genetics (S.K.), Seoul National University, Seoul, South Korea.

    1 shared publication
  • Seung-Shin Yu

    From the Department of Medicine, Cardiovascular Institute, Samsung Medical Center (B.-K.L., J.-O.S., E.-S.J.); Medical Department, MSD Korea Ltd (S.-C.C.); ViroMed Limited, Technology Business Incubator (S.-H.H., J.-M.K., S.-S.Y); and Institute of Molecular Biology and Genetics (S.K.), Seoul National University, Seoul, South Korea.

    1 shared publication

Latest Publications

  • Open Access

    Local Expression of Interleukin-1 Receptor Antagonist by Plasmid DNA Improves Mortality and Decreases Myocardial Inflammation in Experimental Coxsackieviral Myocarditis

    by Byung-Kwan Lim, Seong-Choon Choe, Jae-Ok Shin, Seong-Hyun Ho, Jong-Mook Kim, Seung-Shin Yu, Sunyoung Kim, Eun-Seok Jeon

    Background — The inflammatory cytokines have an important role in the pathogenesis of viral myocarditis. Inerleukin-1 (IL-1) is one of the major cytokines that modulate the outcome of viral infection. Among the methods for in vivo gene transfer, direct injection of plasmid DNA is one that is simple and feasible. In this study, we expressed human IL-1 receptor antagonist (hIL-1Ra) in the mouse heart by direct injection of a novel plasmid vector and evaluated its effects on coxsackieviral (CVB3) myocarditis. Methods and Results — A plasmid vector expressing hIL-1Ra (total 40 μg/mouse) was injected into the heart apex of 8-week-old inbred female Balb/C mice (day 3). On day 0, mice (IL-1Ra-CVB3, n=35) were infected intraperitoneally with 10 4 PFU of CVB3; control mice (pCK-CVB3, n=15) were injected with empty vector on day −3 and infected on day 0. hIL-1Ra was expressed in the heart, reached its peak on day 5, and persisted for 2 weeks. The 14-day survival rate of IL-1Ra-CVB3 was higher (77%) than that of controls (30%, P Conclusion — These results showed that direct injection of the expression plasmid vector into the heart was an effective method to transfer the cytokine gene in vivo, and expressed IL-1Ra in the heart can modulate the deleterious effect of the host immune response in viral myocarditis.